Want to see ENLV full AI Analyst Report?
ENLV Stock Chart & Stats
$1.52
-$0.06(-1.43%)
At close: 4:00 PM EDT
$1.52
-$0.06(-1.43%)
Day’s Range― - ―
52-Week Range$1.02 - $27.15
Previous CloseN/A
Volume17.00K
Average Volume (3M)409.50K
Market Cap
$19.23M
Enterprise Value$28.67
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$641.00K
Price to Earnings (P/E)<0.1
Beta0.65
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)405.30
Shares Outstanding17,485,462
10 Day Avg. Volume293,656
30 Day Avg. Volume409,500
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$80.00Price Target Upside5163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA RMAT DesignationRMAT designation, supported by statistically significant and durable Phase I/IIa results, provides enhanced FDA engagement and a potentially faster development path. This can improve regulatory clarity and strengthen Allocetra’s competitive position as the company advances its 182-patient Phase IIb trial.
Large Disclosed Digital TreasuryThe reported RAIN treasury gives Enlivex a substantial asset base alongside its clinical pipeline and may provide strategic flexibility for funding development and capital allocation. Its dashboard disclosure also creates an identifiable framework for monitoring the treasury’s contribution to the company’s financial position.
Potential Access To Major Growth CapitalIf shareholder and Nasdaq approvals are obtained, the proposed placement could provide significant resources for Allocetra development, debt repayment, and the treasury strategy. The additional three-year put option would extend potential financing capacity, although the transaction remains subject to closing conditions.
Bears Say
No Operating Revenue And Persistent LossesThe absence of meaningful product revenue and continuing operating losses show that Enlivex has not yet established a self-funding commercial model. Persistent negative operating and free cash flow increases dependence on external financing until clinical progress leads to approval, partnerships, or product sales.
Higher-cost, Potentially Dilutive DebtThe amended note reduces monthly payments and removes an immediate default trigger, but it also increases principal and can impose 10% interest under specified conditions. The holder’s flexible conversion formula creates a continuing risk of equity dilution and financing costs over the next several quarters.
Material Exposure To Digital-asset VolatilityA large RAIN-linked treasury introduces business exposure beyond clinical biotechnology, with asset values and liquidity tied to digital-asset market dynamics. This can make the balance sheet and capital strategy more volatile and may compete with the focus and resources required to advance Allocetra.
Enlivex News
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $1.02 and its highest was $27.15 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is $19.23M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 229 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -$0.02 earnings per share for the quarter.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 17,485,462 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.02 in its last earnings report. Following the earnings report the stock price went down -0.38%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in ENLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
ENLV Stock 12 Month Forecast
Average Price Target
$80.00
▲(5163.16% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.18% Mutual Funds
― Other Institutional Investors
99.82% Public Companies and
Individual Investors